Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells
PA Marks, VM Richon, RA Rifkind - Journal of the National …, 2000 - academic.oup.com
Histone deacetylase (HDAC) inhibitors have been shown to be potent inducers of growth
arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. One …
arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. One …
Histone deacetylase inhibitors as new cancer drugs
PA Marks, VM Richon, R Breslow… - Current opinion in …, 2001 - journals.lww.com
Histone deacetylase inhibitors are potent inducers of growth arrest, differentiation, or
apoptotic cell death in a variety of transformed cells in culture and in tumor bearing animals …
apoptotic cell death in a variety of transformed cells in culture and in tumor bearing animals …
Prospects: histone deacetylase inhibitors
M Dokmanovic, PA Marks - Journal of cellular biochemistry, 2005 - Wiley Online Library
Histone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer
agents. Several of these compounds are in clinical trials with significant activity against a …
agents. Several of these compounds are in clinical trials with significant activity against a …
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates
SW Remiszewski, LC Sambucetti… - Journal of medicinal …, 2002 - ACS Publications
Inhibitors of histone deacetylase (HDAC) have been shown to induce terminal differentiation
of human tumor cell lines and to have antitumor effects in vivo. We have prepared …
of human tumor cell lines and to have antitumor effects in vivo. We have prepared …
Histone-deacetylase inhibitors for the treatment of cancer
RK Lindemann, B Gabrielli, RW Johnstone - Cell cycle, 2004 - Taylor & Francis
Histone deacetylase inhibitors (HDACi) are a promising new class of chemotherapeutic drug
currently in early phase clinical trials. A large number of structurally diverse HDACi have …
currently in early phase clinical trials. A large number of structurally diverse HDACi have …
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
S Shankar, RK Srivastava - Advances in experimental medicine and …, 2008 - europepmc.org
Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …
Histone deacetylase inhibitors: from target to clinical trials
WK Kelly, OA O'Connor, PA Marks - Expert opinion on …, 2002 - Taylor & Francis
Transformed cells, characterised by inappropriate cell proliferation, do not necessarily lose
the capacity to undergo growth arrest under certain stimuli. DNA, genetic information, is …
the capacity to undergo growth arrest under certain stimuli. DNA, genetic information, is …
Histone deacetylase inhibitors and cancer: from cell biology to the clinic
H Hess-Stumpp - European journal of cell biology, 2005 - Elsevier
Aberrant gene regulation plays an important role in tumor initiation and progression, and the
acetylation of histones is a well understood key component of gene regulation. Histone …
acetylation of histones is a well understood key component of gene regulation. Histone …
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers
VM Richon, X Zhou, RA Rifkind, PA Marks - Blood Cells, Molecules, and …, 2001 - Elsevier
Transformed cells have escaped normal growth regulatory signals and may be blocked at
discrete states of differentiation prior to the stage of terminal cell division and/or apoptosis …
discrete states of differentiation prior to the stage of terminal cell division and/or apoptosis …
Histone deacetylase inhibitors in cancer therapy
RR Rosato, S Grant - Cancer biology & therapy, 2003 - Taylor & Francis
Histone deacetylase inhibitors (HDAC inhibitors) represent a novel class of antineoplastic
agents that act by promoting acetylation of histones, leading in turn to uncoiling of chromatin …
agents that act by promoting acetylation of histones, leading in turn to uncoiling of chromatin …